In this interactive session, Life Sciences CEOs will explain what their concerns are while evaluating opportunities outside their organizations and maximizing the opportunities inside their organizations. Topics will include:
- How does a CEO incorporate shareholder valuation into the due diligence process?
- How do you measure acceptable risk?
- What due diligence factors do you use in selecting a partner for a collaboration agreement?
Panelists include: George Daniloff, CEO, Carbylan BioSurgery; Dinesh V. Patel, Ph.D., President and CEO, Arête Therapeutics; Tom Moran, Of Counsel, Foley; Jay Sheppard, President and Chief Executive Officer, Relypsa, Inc.; and James A. D. Smith, President and Chief Executive Officer, Genelabs.
Related Insights
July 8, 2025
Energy Current
What’s the Future for Renewable Energy Tax Credits in Congress?
The One Big Beautiful Bill Act (OBBB) has a significant impact on the renewable energy sector, particularly with changes in the phase-out…
July 8, 2025
Energy Current
Executive Order on PTC and ITC Beginning of Construction
President Trump yesterday issued an executive order, “Ending Market Distorting Subsidies for Unreliable, Foreign Controlled Energy…
July 8, 2025
Foley Viewpoints
The HDHP Telehealth Safe Harbor Returns – For Good This Time
President Trump signed into law the One Big Beautiful Bill Act (the bill) on July 4, 2025. The telehealth safe harbor, which allowed…